VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial ...

We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement ...

The inducement stock options have an exercise price of $16.37 per share, the closing price of ImageneBio’s common stock on July 28, 2025, are non-qualified stock options, have a ten-year term and vest ...

Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non‑dilutive ...

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten ...

In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with ...

(“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for ...

Over the past few days, shares of Pheton have experienced an extraordinary and unexpected decline in its share price, which the Company believes may have been triggered by a speculative article ...

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more ...

CEO, David Bailey added, “This launch marks our inaugural Pediatric Plating Platform and underscores our commitment to expanding the platform into the most comprehensive plating portfolio in pediatric ...

NeuroPace will continue to work with CMS on MS-DRG improvements and other reimbursement related topics. The company remains committed to ensuring that reimbursement policy keeps pace with clinical ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024; Dupixent ® global net sales (recorded by Sanofi) increased 22% to $4.34 billion ; EYLEA HD ...